SLC5A2 and type 2 diabetes mellitus: Sodium glucose cotransporter-2 (SGLT2) inhibitors have emerged as a promising new class of glucose-lowering drugs for the management of type 2 diabetes [11], and dapagliflozin is the most selective, reversible, and orally active SGLT2 inhibitor for wide clinical use [12].